someone should tell me can any company pay 42m in Nigeria?

BENARI:

Since I was born, and now I am getting old, I have never seen the Muslim North doing Charity toward Christians; its always the Christians giving to them and yet, they hate the Christians so badly.

Sometimes, I wonder the motive behind Some Christians falling over themselves to give to this people in the full glare of the camera. All the same, giving is Good, especially when the recipient is appreciative.

Let give it to them they are physical, mentally and spiritually poor....

both side can be use depending on situation you find yourself....but faith is very essential

[sub][/sub][ur

bastard of the highest order in Yoruba land

try this in China by now KANU would have dancing with the ghost.....Nigeria!! I pity the future of this nation

may God bless the writer.....I'm with you and so blessed

if I ask some people, what is your business? they answered I work in the bank I ask them again, Do you own the bank?

the dog wey enter lion den and come back dey lucky

ALABACONNECT:
Glory!!!!!!!!!!! Victory is ours

people of this word get mind ooo....to the extend they can criticise work of God, wetin tithe and offering do for them

how alimodu sheriff survived the attack? this man with juju

https://nationalinterest.org/blog/buzz/north-korea-has-trillions-dollars-mineral-wealth-134282
This north Korea is highly bless in iron ore rare earth metal check the link above.

Remembrance of the man of great mantle.....babalola your work still speak

carry on my VP

how Do u post new on nairaland can you please show me

The Israeli scientists who say a single placenta
can treat 20,000 coronavirus sufferers are
hopeful, as some patients have shown
improvement while the company shares have
skyrocketed.
Pluristem Therapeutics uses placentas to grow
smart cells, and programs them to secrete
therapeutic proteins in the bodies of sick people.
It has just treated its first American COVID-19
patient after treating seven Israelis.
There is no follow-up data on the American
patient, but the company reported that as of a
follow-up on April 7, all seven Israelis had
survived and three were on target to soon move
off the ventilator, while one had shown
deterioration in respiratory parameters.
Two of the four Israelis with multiple organ
failure showed clinical recovery as well as
respiratory improvement. All patients were one
week after treatment at time of follow-up, apart
from one, who received treatment after the
others and whose health update wasn’t reported.
The treatment of select patients doesn’t constitute
a clinical trial and there is no control group, but
company CEO and president Yaky Yanay said that
a trial will come soon and, once conducted, he
hopes that “approval can be very fast.” Upon
receiving the green light from regulators, he said,
massive quantities of treatment can be prepared.
“We can manufacture cells to treat thousands
very quickly,” he said.
The market appears to share his optimism. For
most of 2020 shares have traded at under $4;
now the price is close to $10.
But public health expert Manfred Green said he is
“very very cautious” about such innovations.
Green, founding director of the Israel Center for
Disease Control and director of the University of
Haifa’s international masters program in public
health, said: “I don’t have any feeling this is
going to work. This is a viral disease, not
something from outer space, and for viral
diseases we’ve always struggled to find
treatment.”
Yanay said that his innovation will save lives,
both by improving the health of critical patients,
and by freeing up space in intensive care units
for others.
“I think this will have a huge impact because
currently the battle is in the ICUs,” he said. “We
need to take people off ventilation machines and
get them out of ICUs.”
The treatment is waiting on regulatory approval,
but Pluristem is receiving approvals on a patient-
by-patient basis in Israel and the US, hoping to
gather enough information for full approval. In
Israel it has worked so far at three hospitals
under a compassionate use program, and at Holy
Name Medical Center in New Jersey it was
allowed to administer cells under the
Coronavirus Treatment Acceleration Program, an
emergency mechanism for possible therapies.
Treatment consists of 15-milliliter doses of cells
— known as PLacental eXpanded cells —
administered in simple inter-muscular injections.
Once in the body, Yanay said that the cells
become like “a small factory that generates
therapeutic proteins.”
He explained: “Most drugs we know are
administered in the quantity we need, but this is
a ‘drug’ that can sense the human body’s
environment, and based on the signals that the
cells receive from the body, they secrete
therapeutic proteins that push the body toward
regeneration.”
The cells secrete two types of proteins. One
reduces inflammation; the other is to regulate the
immune system. Yanay hopes these so-called
immunomodulation proteins can slam the brakes
on the immune system to stop it turning on itself,
as commonly happens with critical coronavirus
patients.
“They stop the body from attacking its own
organs by having the placenta cells secrete
immunomodulatory factors, basically relaxing the
immune system, as the other proteins reduce
inflammation,” said Yanay.
He elaborated: “Patients who are in severe
condition and dying are actually dying from a
severe respiratory condition. What is actually
happening is there is a very high level of
inflammation and at a certain point the immune
system of the patient will attack [the patient],
mostly in the lungs.”
Until now, Pluristem’s technology has been
largely used to treat people suffering from poor
blood flow to the legs, but the company’s
scientists were able to quickly repurpose the cells
to treat coronavirus patients.
“We take cells from the placenta after full-term
delivery and we have developed technology to
expand the cells to very large numbers, in an
environment that mimics the human body,”
Yanay said. “The technology allows us to treat
more than 20,000 people from a single placenta.”
His team “programs” the cells, which then have a
wide range of proteins they can secrete. The cells
don’t just deliver the proteins but also “adjust the
level of secretion based on signals they receive
from the body,” he said.
Yanay stated that Pluristem, which is based in
Haifa, will carry on treating people using patient-
by-patient approvals, while working as quickly as
possible for full approval by regulators.
“We are receiving many inquiries and requests
for treatment from health care providers and
families worldwide,” he said. “In parallel with
our planned clinical trial, we expect to continue
treating patients under compassionate use
through the appropriate regulatory clearances in
the United States and Israel, as well as expanding
treatment under compassionate use in other
countries.
“Our main focus remains, however, the initiation
of a multinational clinical study,” he said, adding
that he was hopeful “cell therapy is a very good
candidate to tackle a complex disease that is
attacking several organs.”
https://www.timesofisrael.com/israeli-company-hopes-to-treat-coronavirus-patients-with-placenta-cells/

keep your mouth shut.....work in silence and let the result speak for you..... now BH know your are around so they restructure themself...unwise buratai, must you tell us you are now in borno.

I tell you

God will rescued you.....